Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Bial

Tracked across 1 events · 6 articles · First seen May 26, 2026 · Last active Jun 09, 2026

Sentiment
-70
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 -70
Business
Impact: Bial announced the completion of its Phase 2b ACTIVATE study for Pariceract, which subsequently failed to meet its primary and key secondary efficacy endpoints, leading to the discontinuation of the drug's development for GBA1-associated Parkinson s disease. This represents a significant setback for Bial's R&D efforts in neurosciences.
May 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Bial live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.